March 4, 2010

SymBio Pharmaceuticals Limited.
Fuminori Yoshida
Representative Director
President and Chief Executive Officer

SymBio Initiates Japan Phase 2 Trial of Bendamustine HCl (SyB L-0501) in Aggressive
Non-Hodgkin’s Lymphoma
TOKYO, Japan, March 4, 2010 -- SymBio Pharmaceuticals Limited (”SymBio”) today announced thatit has initiated a phase 2 clinical trial for its lead drug candidate, bendamustine hydrochloride (SyBL-0501), in refractory and relapsed aggressive non-Hodgkin’s lymphoma (NHL) in Japan inaccordance with the license agreement signed with Eisai Co., Ltd.
SymBio submitted A New Drug Application (NDA) for SyB L-0501 to the Pharmaceuticals andMedical Devices Agency (PMDA) in Japan under priority review on October 30, 2009, after receiving
orphan drug designation for the treatment of refractory and relapsed indolent NHL and mantle cell
lymphoma. With this phase 2 trial in aggressive NHL, the Company seeks to expand the use of thisdrug in a wider range of indications. The trial has been designed as an international collaborative
study of bendamustine HCI in combination with rituximab for the treatment of aggressive NHL inKorea and Japan. A clinical trial application was submitted to the Korean Food and Drug
Administration (KFDA) on February 17, 2010, and the trial is expected be underway this April.
SyB L-0501, in combination with rituximab, proved to be both safe and efficacious during the earlier
Japan phase 1 trial conducted in patients with refractory and relapsed aggressive NHL.

[SyB L-0501]
SymBio holds exclusive rights to SyB L-0501, the Company’s first drug candidate, from Astellas
Deutschland GmbH for development and commercialization in Japan, China (HK), Taiwan, Koreaand Singapore. SymBio and Eisai executed a license agreement for co-development andcommercialization of SyB L-0501 in Japan in August, 2008, followed by a second license agreement for
the exclusive development and commercialization of SyB L-0501 in Korea and Singapore in May, 2009.
SymBio and Cephalon executed a license agreement for development and commercialization of SyB
L-0501 in China in March, 2009, (Development and commercialization rights of bendamustine HCI
are held by Cephalon, Inc. in North America, and by Mundipharma International Corp. Ltd. inEurope.) The drug is currently on the market in the U.S., and is listed as first line therapy for indolent
NHL and mantle cell lymphoma in NCCN (National Comprehensive Cancer Network) Clinical
Practice Guidelines in Oncology, the recognized standard for clinical policy in oncology.

[Company Profile]
SymBio Pharmaceuticals Ltd. was established in March, 2005 by Fuminori Yoshida, who previously
served as both Corporate VP of Amgen Ltd. and President of Amgen Japan (currently Takeda Bio
Development Center Limited). The company’s underlying corporate mission is “delivering hope topatients in need” as it aspires to be a leading specialty pharmaceutical company in the Asia Pacific
Rim dedicated to addressing underserved medical needs in the areas of oncology and hematology.

[Contact]
SymBio Pharmaceuticals Limited.
Hiroki Maekawa,
Corporate Officer,
Head of Corporate Division
Tel: +081(0)3 5472 1125
e-mail: Please send your inquiry through “INQUIRY” in our homepage
URL: http://www.symbiopharma.com/